Varro Holdings is at the forefront of developing innovative technologies aimed at the rapid detection of infectious pathogens, particularly respiratory ones. Their primary focus is on creating biodetector devices that can identify pathogens in breath and indoor air with remarkable speed and accuracy. The company is commercializing a technology initially developed by Washington University in St. Louis, which allows for the immediate detection of SARS-CoV-2 and other pathogens. Varro's devices are designed to be inexpensive, user-friendly, and capable of delivering results in under 60 seconds, matching the sensitivity of traditional PCR testing. This approach aims to significantly reduce the time and cost associated with infectious disease testing while enhancing the sensitivity and specificity of pathogen detection.

In addition to their breath-based diagnostic device, Varro is also developing an air quality monitor that can simultaneously detect multiple airborne pathogens in indoor environments. This technology is crucial for preventing disease transmission and controlling outbreaks. Varro's commitment to fostering an open-source community further supports rapid deployment and collaboration in the fight against infectious diseases. By leveraging advanced microbiology, aerosol engineering, and electronics, Varro Holdings is positioned to make a substantial impact on public health and disease prevention strategies.

United States

Our purpose is to disrupt disease transmission. At Varro Life Sciences, we develop innovative products and technologies that make a global impact across economic and cultural borders. We are ambitious and dedicated in our pursuit to leverage technology that saves lives, ensures safe environments, and prevents future pandemics. The company was established in January 2020 as Y2X Life Sciences, and the company name was changed in October 2024.

Varro Holdings

Company Details